Cosentyx (secukinumab)

pCPA File Number: 20881
Negotiation Status:
Concluded with an LOI
Indication(s):
Psoriasis, moderate to severe plaque
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
SR0407-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: